Differentiation status in neuroblastoma strongly affects clinical outcomes and inducing differentiation is a treatment strategy in this disease. However, the molecular mechanisms that control neuroblastoma differentiation are not well understood. Here we show that high-level HOXC9 expression is associated with neuroblastoma differentiation and is prognostic for better survival in neuroblastoma patients. HOXC9 induces growth arrest and neuronal differentiation in neuroblastoma cells by directly targeting both cell cycle-promoting and neuronal differentiation genes. HOXC9 expression is upregulated by retinoic acid (RA) and knockdown of HOXC9 expression confers resistance to RAinduced growth arrest and differentiation. Moreover, HOXC9 expression is epigenetically silenced in RA-resistant neuroblastoma cells and forced HOXC9 expression is sufficient to inhibit their proliferation and tumorigenecity. These findings identify HOXC9 as a key regulator of neuroblastoma differentiation and suggest a therapeutic strategy for RA-resistant neuroblastomas through epigenetic activation of HOXC9 expression.
Introduction
Neuroblastoma is a common childhood malignant tumor of the sympathetic nervous system. Histologically, neuroblastoma is a heterogeneous group of tumors, ranging from tumors with predominantly poorly differentiated neuroblasts to those largely consisting of fully differentiated sympathetic neurons (1, 2) . It has long been recognized that neuroblastoma differentiation states are of prognostic significance: patients with neuroblastomas of differentiating histology have significantly better survival than those with poorly differentiated neuroblastomas (3) (4) (5) (6) . This positive correlation between neuroblastoma differentiation and favorable outcome has also been confirmed at the molecular level by microarray studies (7, 8) .
Retinoic acid (RA) is an effective inducer of neuroblastoma cell differentiation (9, 10) . As a result, RA has been used in clinic as a differentiation agent for treatment of high-risk neuroblastomas (11, 12) . Importantly, high-risk neuroblastoma patients treated with 13-cis-RA after bone-marrow transplant showed a significant improvement in event-free survival (13, 14) . However, resistance to RA has been observed in both neuroblastoma cell lines and patients, which presents a major barrier to successful RAbased therapy (11, 12) . Identification of downstream mediators of the RA-induced differentiation program may offer opportunities to bypass resistance to RA.
Homeobox (HOX) proteins are key mediators of RA action in the development of nervous systems (15, 16) . The HOX family of transcription factors function as master regulators of morphogenesis and cell fate specification (17) (18) (19) . RA-induced differentiation of neuroblastoma cells is associated with increased HOX expression (20) (21) (22) . However, the roles of HOX genes in RA-induced differentiation and the underlying 
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Cell Lines and Culture
The human neuroblastoma cell lines BE (2) 
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(0.01-0.1%) was used as negative control (untreated). Cells were examined and phase contrast images captured using an Axio Observer microscope and the software AxioVision (Carl Zeiss MicroImaging, Thornwood, NY).
Quantitative RT-PCR
Cells were lysed with Trizol (Invitrogen) for total RNA purification. Reverse transcription was performed using SuperScript II Reverse Transcriptase (Invitrogen). qRT-PCR was performed using either a TaqMan gene expression assay kit (Applied Biosystems, Foster City, CA) or a RT 2 SYBR green/Fluorescein PCR master mix (SABiosciences, Frederick, MD). Primer sequences are described in Supplementary Materials and Methods. PCR reactions in triplicate were performed using an iQ5 real-time PCR system (Bio-Rad, Hercules, CA).
Analyses of Patient Data
Patient data used in this study were described previously (23, 24) . Gene expression datasets were obtained from the Oncogenomics Database (http://pob.abcc.ncifcrf.gov/cgi-bin/JK) (25) . Cluster analysis was performed using geWorkbench (version 2.0.0) and total linkage with Spearman's rank correlation.
Kaplan-Meier analysis was conducted online, and the resulting survival curves and p values (log-rank test) were downloaded. All cutoff values for separating high and low expression groups were determined by the online Oncogenomics algorithm (25) .
Immunoblotting and Immunofluorescence
Research. Immunoblotting was conducted according to standard procedures using primary antibodies detailed in Supplementary Materials and Methods. Horseradish peroxidaseconjugated goat anti-mouse and goat anti-rabbit IgG (Santa Cruz Biotechnology) were used as secondary antibodies. Proteins were visualized using a SuperSignal West Pico chemiluminescence kit (Pierce, Rockford, IL) and quantified using ImageJ (version 1.42q). Films were exposed for various times for quantification of target proteins within their linear range of detection. Alternatively, proteins levels were quantified using the Supplementary Table S4 .
Statistical Analysis
Research. 
Results
High HOXC9 expression is associated with neuroblastoma differentiation
To gain insight into the molecular mechanisms that control the differentiation of Fig. S1C ). By contrast, RA failed to induce HOXC9 in SK-N-AS cells (Fig. 1A) , a RA-resistant neuroblastoma cell line (28, 29) (Supplementary Fig. S1C ).
These findings suggest a correlation between RA responsiveness and HOXC9 induction in human neuroblastoma cells.
We then investigated the correlation of HOXC9 expression levels with differentiation states in primary neuroblastomas, using the Oberthuer microarray dataset available from the online Oncogenomics Database (25) . The dataset includes a cohort of 251 patients with neuroblastomas representative of various tumor stages and genetic alterations (24) . A hierarchical cluster analysis revealed an association of HOXC9 with differentiation markers (Fig. 1B) . When the tumors were separated into HOXC9 high and low expression groups, tumors of the high HOXC9 group expressed significantly higher levels of differentiation markers and lower levels of proliferation markers ( Meier analysis of progression-free survival for the Oberthuer dataset showed that high HOXC9 expression was associated with good prognosis, whereas low HOXC9 expression was associated with poor outcome ( Fig. 2A) . Moreover, decreased HOXC9 expression correlated significantly with advanced tumor stages (Fig. 2B) . Interestingly, Stage 4S tumors expressed HOXC9 at levels similar to those of Stage 1 tumors (Fig.   2B ). It is known that Stage 4S patients have a high degree of spontaneous regression and favorable prognosis (30, 31) . We confirmed that high HOXC9 expression is prognostic for favorable outcome with the Seeger dataset ( Fig. 2C and D) , which includes a cohort of 102 neuroblastoma patients with metastatic tumors lacking MYCN amplification (23) . Together, our analyses of two independent microarray datasets indicate that HOXC9 is a prognostic marker in neuroblastoma, independent of the status of MYCN amplification.
We also examined the prognostic values of HOXD1, HOXD8, and other member of the HOX-9 paralog group, HOXA9, HOXB9 and HOXD9, using data available from the Seeger dataset. Kaplan-Meier analysis revealed no significant correlation between their expression levels and disease outcome ( Supplementary Fig. S2 ). These results indicate the specificity of HOXC9 as a prognostic marker for neuroblastoma.
As HOX genes are expressed during embryonic development in a time sequence from 3ƍ to 5ƍ according to their physical positions along the chromosomes, known as temporal colinearity (32) , and younger patient age at diagnosis is associated with good prognosis (5), we examined the correlation of HOXC9 expression levels with patient age at diagnosis using information available from the Oberthuer dataset (24) . We chose the cutoff at 18 months of age as it gave the most significant p value for prognostic (Fig. 2E) . The younger age group expressed significantly higher levels of HOXC9 than the older age group (Fig. 2F) , demonstrating a correlation of high HOXC9 expression with younger age at diagnosis.
HOXC9 induces G1 arrest
We next examined the functional consequence of high HOXC9 expression in neuroblastoma cells using a "Tet-Off" inducible system (Supplementary Fig. S3A ). The level of HOXC9 expression in BE(2)-C/Tet-Off/HOXC9 cells cultured in the absence of doxycycline was HOXC9 induction in BE(2)-C cells completely blocked cell proliferation, with 90% of cells arrested in the G1 phase ( Fig. 3A and B) . This growth arrest phenotype could be reversed and re-induced by adding and removing doxycycline, respectively (Supplementary Fig. S3B ), indicating that the phenotype is dependent on continuous HOXC9 expression. In addition, HOXC9 induction markedly inhibited the growth of BE(2)-C cells in soft agar and in immunodeficient mice ( Fig. 3C and D) . We obtained similar results with SK-N-DZ and SK-N-F1 cells (Supplementary Fig. S4 ). By contrast, overexpression of HOXB4, B5 or B6 either enhanced (HOXB4 and B5) or had no apparent effect (HOXB6) on the growth of BE(2)-C cells in culture (data not shown) and in soft agar ( Supplementary Fig. S5 ). Together, these findings indicate a specific antigrowth activity for HOXC9 in neuroblastoma cells.
HOXC9 represses cell cycle-promoting genes
HOX proteins can act as both transcriptional activators and repressors (17, 33) . To gain insight into the molecular mechanism underlying HOXC9-induced G1 arrest, we analyzed the gene expression profiles of BE(2)-C cells with or without HOXC9 induction. Ectopic HOXC9 expression either decreased or had no significant effect on the transcription of genes encoding CDK inhibitors (CDKNs) (Supplementary Table S1 ).
In addition, overexpression of CDKN1A/p21 or CDKN1B/p27 had little impact on the proliferation of BE(2)-C cells (Supplementary Fig. S6 ). Thus, regulation of CDKN expression is unlikely a major mechanism for HOXC9-induced G1 arrest. By contrast, HOXC9 induction led to a marked downregulation of cyclin A2, B1, E2, CDK1 and CDK2, which, collectively, are required for the cell cycle progression through S to M phases, as determined by microarray (Supplementary Table S2 ), qRT-PCR (Fig. 4A) , and immunoblotting (Fig. 4B) . We obtained similar results with SK-N-DZ and SK-N-F1 cells ( Supplementary Fig. S7 ). Protein stability assays showed that HOXC9 induction had no significant effects on the half-life of cyclin A2, B1 and E2 (Supplementary Fig.   S8 ). Together, these results demonstrate that HOXC9-induced downregulation of cyclins and CDKs occurred primarily at the transcription level.
The transcription of cyclin genes is regulated in a cell cycle-dependent manner (34) . Thus, the observed downregulation of cyclins could be a consequence of cell cycle arrest in G1. Alternatively, HOXC9 may directly repress the transcription of cyclin genes, given the well-documented transcriptional repressor activity of HOX proteins (17).
Since we failed to identify any CDKNs that may function downstream of HOXC9 to induce G1 arrest, we investigated the possibility of cyclin genes as direct targets of 
HOXC9, using cyclin B1 as an example. HOX proteins bind DNA sequences with a conserved TAATT/AA-motif (17, 33) . Sequence examination revealed multiple potential HOX-binding sites within the human CCNB1 promoter. ChIP-qPCR analysis revealed specific interaction of HOXC9 with the promoter region spanning from -430 to -178 (7.7 fold enrichment relative to IgG control) (Fig. 4C) , demonstrating that HOXC9 directly interacts with the CCNB1 promoter in the context of chromatin.
We next performed luciferase reporter assays. The parental promoter-less firefly luciferase construct (pLuc2P) showed minimal activity in BE(2)-C cells. Placing the CCNB1 promoter sequence (-820 to +175) upstream of the luciferase gene (CCNB1-pLuc2P) led to a more than 20-fold increase in the luciferase activity. Co-transfection of CCNB1-pLuc2P with a HOXC9-expressing construct strongly repressed the luciferase expression (Fig. 4D, CCNB1-pLuc2P ). Importantly, a 3-base mutation of the putative HOX-binding site (-382 to -377) from TATTAA to GCTGAA largely abrogated the repressive activity of HOXC9 (Fig. 4D, CCNB1mut3-pLuc2P) . Taken together, these data demonstrate that HOXC9 directly targets CCNB1 for repression.
We further examined the chromatin state of the CCNB1 promoter by ChIP-qPCR assays using antibodies against trimethylated histone H3 at lysine 4 (H3K4me3) or H3K27me3, which marks a transcriptionally active or silenced state, respectively (35) .
Consistent with the observed transcriptional repression of CCNB1, ChIP-qPCR assays revealed a marked increase (47-fold) in the level of H3K27me3 associated with the transcriptional start site of CCNB1 following HOXC9 induction (Fig. 4E) . We observed no significant levels of H3K4me3 at the CCNB1 promoter before and after HOXC9
Research. (Fig. 4E) . These findings indicate that ectopic expression of HOXC9 confers a transcriptionally silenced state on the CCNB1 promoter.
HOXC9 induces neuronal differentiation
BE(2)-C cells cultured under the condition of HOXC9 induction for an extended period of time displayed morphologic features of neuronal differentiation, such as small and rounded cell bodies, and extensive neurite outgrowth (Fig. 5A) . The differentiation was confirmed at the molecular level. HOXC9 induction in BE(2)-C (Fig. 5B ) and other neuroblastoma cell lines ( Supplementary Fig. S7B and C) resulted in marked downregulation of paired-like homeobox 2B (PHOX2B), a sympathetic neuronal progenitor marker that is downregulated during sympathetic neuron differentiation (36) and RA-induced differentiation ( Supplementary Fig. S9A and B) . HOXC9 induction also led to significant upregulation of neuronal differentiation markers including neurofilament medium (NEFM) and RET, the receptor for glial cell-derived neurotrophic factor ( Fig. 5B and C). Both NEFM and RET are target genes of RA in neuroblastoma cells (37, 38) ( Supplementary Fig. S9A-C) . Additional neuronal genes that were upregulated by HOXC9 include those encoding neurofilament light (NEFL), neural cell adhesion molecule 2 (NCAM2) and neurexin 1 (NRXN1) and proteins functioning in the induction of neurite outgrowth, such as neurofascin (NFASC) and neurensin (NRSN1) (39, 40) (Supplementary Table S3 ). Together, these findings suggest that HOXC9 induces neuronal differentiation by transcriptional activation of neuronal genes.
We next investigated whether HOXC9 can directly target neuronal genes, using NEFM as a model. Examination of NEFM 5' and 3' flanking sequences revealed three potential HOX-binding sites with a perfect match to the consensus TAATT/AA-motif (Fig. 5D) . ChIP-qPCR analysis demonstrated specific interaction of HOXC9 with the 5P2 and 3P1 sites (40-and 16-fold enrichment, respectively, relative to IgG control) (Fig. 5D) . These results suggest that NEFM is a direct target gene of HOXC9.
HOXC9 is a mediator of RA action
Since RA induced HOXC9 and ectopic HOXC9 expression largely recapitulated the phenotype of growth arrest and neuronal differentiation induced by RA at both the cellular and molecular levels ( Supplementary Fig. S1 and S9), we investigated the possibility of HOXC9 as a mediator of RA action. We tested three lentiviral constructs expressing short hairpin RNA (shRNA) sequences against human HOXC9 (HOXC9sh) and they all significantly reduced HOXC9 expression in BE(2)-C cells ( Supplementary   Fig. S10A ). The functional specificity of these HOXC9sh constructs was demonstrated by their rescue of the G1-arrest phenotype induced by HOXC9 ( Supplementary Fig.   S10B and data not shown). Since we failed to obtain a significant number of viable BE(2)-C cells expressing HOXC9sh-10, we performed the following experiments with BE(2)-C cells expressing either HOXC9sh-9 or -12, with essentially the same results. BE(2)-C cells with HOXC9 knockdown were highly resistant to RA-induced neuronal differentiation and growth arrest, as determined by morphology, cell cycle analysis, proliferation and soft agar clonogenic assays (Fig. 6A-C) . In addition, knockdown of HOXC9 expression markedly inhibited the ability of RA to downregulate cyclins ( Fig. S11 ). Collectively, these results demonstrate that HOXC9 is a key mediator of RA action in neuroblastoma cells.
HOXC9 inhibits the proliferation and tumorigenicity of RA-resistant neuroblastoma cells
The neuroblastoma cell line SK-N-AS is highly resistant to RA (28, 29) (Supplementary   Fig. S12A ). Interestingly, although BE(2)-C and SK-N-AS cells expressed similar levels of RA receptors ( Supplementary Fig. S12B ), RA failed to induce HOXC9 and RET in SK-N-AS cells (Fig. 1A and Supplementary Fig. S12C ). This observation prompted us to Fig. S12D ).
Using SK-N-AS cells with inducible expression of HOXC9 in the absence of doxycycline ( Supplementary Fig. S13A ), we found that HOXC9 induction completely inhibited the growth of SK-N-AS cells (Fig. 7B) , with a marked reduction in the number of KI67 + cells (Supplementary Fig. S13B ). HOXC9 also significantly upregulated RET expression ( Fig. 7C) and exhibited a marked anti-tumorigenic activity in SK-N-AS cells
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( Fig. 7D) . Together, these data indicate that the resistance of SK-N-AS cells to RA is associated with epigenetic silencing of the HOXC9 promoter and forced HOXC9 induction is sufficient to inhibit the proliferation of RA-resistant cells.
Discussion
The present study provides several lines of evidence for HOXC9 as a key regulator of neuroblastoma differentiation. First, HOXC9 is expressed at significantly higher levels in It is well established that during embryonic development, the expression of HOX genes is spatially and temporally regulated, showing a direct correlation between their linear arrangement along the chromosomes and the timing and anterior-posterior boundaries of their expression (42) . This colinearity is essential for the developmental function of HOX genes in specifying positional identities of tissues along the anteriorposterior axis. We speculate that HOXC9 expression might also be spatially and temporally regulated in neuroblastomas. We found that tumors from younger patients (<18 months) expressed HOXC9 mRNA at significantly higher levels than tumors from older patients (>18 months), suggesting that neuroblastomas initiated during early embryonic development are more likely to express higher levels of HOXC9. It has also been noted that the site of the primary tumor is of prognostic value: tumors developed in the neck and thorax are associated with better outcome, whereas those of adrenal or abdominal origin are associated with worse outcome (4, 5) . In addition, it has been reported that higher proportions of neuroblastomas in the neck and thorax are of differentiating histology as compared with other sites (43) . Although no information is currently available regarding the correlation of HOXC9 expression levels and the primary sites of neuroblastomas, based on the strong association of HOXC9 expression with neuroblastoma differentiation states and outcome, we suspect that tumors developed in the neck and thorax might express higher levels of HOXC9 compared with 
